Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 27 clinical trials
Exemestane Letrozole or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

are exemestane, anastrozole, letrozole. The purpose of this study is to find out whether it is better to receive exemestane, anastrozole, or letrozole to improve the chance that the

estrogen
estrogen receptor
exemestane
anastrozole
hormone therapy
  • 33 views
  • 07 Nov, 2020
  • 1 location
A Study of Lerociclib in Participants With Advanced Breast Cancer

first line endocrine therapy such as tamoxifen, anastrozole, or letrozole (2L population). All premenopausal or perimenopausal female participants, and all male participants, must be receiving goserelin

  • 0 views
  • 15 Jun, 2022
  • 6 locations
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) (HERMIONE-7)

The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.

measurable disease
abemaciclib
her2-negative breast cancer
HER2
estrogen
  • 39 views
  • 25 Mar, 2022
  • 38 locations
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease. (SERENA-4)

The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of

  • 0 views
  • 04 Oct, 2022
  • 202 locations
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib or abemaciclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with

  • 35 views
  • 04 Oct, 2022
  • 142 locations
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

modulator (such as tamoxifen) or an aromatase inhibitor (anastrozole, letrozole, exemestane) or fulvestrant (Faslodex). Premenopausal women and men may also receive a drug called an LHRH (luteinizing

estrogen receptor
exemestane
gnrh
invasive breast cancer
anastrozole
  • 3 views
  • 19 Feb, 2022
  • 55 locations
Anastrozole Palbociclib Trastuzumab and Pertuzumab in HR-positive HER2-positive Metastatic Breast

This is a multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab is proposed as first-line therapy in metastatic hormone receptor-positive, HER2-positive breast

mammogram
pertuzumab
ejection fraction
erbb2
gene amplification
  • 38 views
  • 09 Jul, 2021
  • 7 locations
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer

This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment

liver metastasis
measurable disease
carboplatin
estrogen
clear cell adenocarcinoma
  • 5 views
  • 04 Oct, 2022
  • 2 locations
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

This phase II trial studies how well anastrozole and letrozole after surgery work in treating patients with stage I-III breast cancer. Drugs, such as anastrozole and letrozole, may stop the

neutrophil count
estrogen receptor
carcinoma
invasive breast cancer
platelet count
  • 0 views
  • 16 Jun, 2022
  • 3 locations
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

The purpose of this study is to test any good and bad effect of the study drug, onapristone extended-release (ER) alone and in combination with anastrozole.

  • 7 views
  • 25 Jul, 2022
  • 8 locations